Clinical significance of immunohistochemical expression of cancer/testis tumor-associated antigens (MAGE-A1, MAGE-A3/4, NY-ESO-1) in patients with non-small cell lung cancer

Tumori

Volumn 100, Issue 1, 2014, Pages 60-68

  Grah, Josip Joachim ^a   Katalinic, Darko ^a   Juretic, Antonio ^a   Santek, Fedor ^a   Samarzija, Miroslav ^a  

^a KBC Zagreb   (Croatia)

Author keywords

MAGE A1; MAGE A3 4; Non small cell lung cancer; NY ESO 1

Indexed keywords

MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3; MELANOMA ANTIGEN 4; NY ESO 1 ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; TUMOR NECROSIS; TUMOR VOLUME; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MELANOMA-SPECIFIC ANTIGENS; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM PROTEINS; NEOPLASM STAGING; TESTICULAR NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84896917173     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/1430.15817     Document Type: Article

References (50)

1. Jemal A, Thomas A, Thun M: Cancer statistics. CA Cancer J Clin, 52: 23-47, 2002.
2. Ramalingam S, Belani C: Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist, 13: 5-13, 2008.
3. Katzel JA, Fanucchi MP, Li Z: Recent advances of novel targeted therapy in non-small cell lung cancer. J Hematol Oncol, 2: 2, 2009.
4. Boon T, Old LJ: Cancer tumor antigens. Curr Opin Immunol, 9: 681-683, 1997.
5. Groeper C, Gambazzi F, Zajac P, Bubendorf L, Adamina M, Rosenthal R, Zerkowski HR, Heberer M, Spagnoli GC: Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer. Int J Cancer, 120: 337-343, 2006.
6. McCann J: Can skin cancers been minimized or prevented in organ transplanted patients? J Natl Cancer Inst, 91: 911-913, 1999.
7. Dunn GP, Old LJ, Schreiber RD: The three Es of cancer immunoediting. Ann Rev Immunol, 22: 329-360, 2004.
8. Zendman AJ, Ruiter DJ, Van Muijen GN: Cancer/testis-associated genes: identification, expression profile, and putative function. J Cell Physiol, 194: 272-288, 2003.
9. De Smet C, De Backer O, Faraoni I, Lurquin C, Brasseur F, Boon T: The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci USA, 93: 7149-7153, 1996.
10. Sigalotti L, Fratta E, Coral S, Tanzarella S, Danielli R, Colizzi F, Fonsatti E, Traversari C, Altomonte M, Maio M: Intratumor heterogenecity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine. Cancer Res, 64: 9167-9171, 2004.
11. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Castillejo JA, Navarro G, San Jose-Eneriz E, Garate L, Cordeu L, Cervantes F, Prosper F, Heiniger A, Torres A: Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukemia. Haematologica, 20: 153-162, 2007.
12. Novellino L, Castelli C, Parmiani G: A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother, 54: 187-207, 2005.
13. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT: Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev, 188: 22-32, 2002.
14. Simpson AJ, Cabalero OL, Jungbluth A, Chen YT, Old LJ: Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer, 5: 615-625, 2005.
15. Bolli M, Kocher T, Adamina M, Guller U, Dalquen P, Haas P, Mirlacher M, Gambazzi F, Harder F, Heberer M, Sauter G, Spagnoli GC: Tissue microarray evaluation of melanoma antigen E (MAGE) tumor-associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma. Ann Surg, 236: 785-793, 2002.
16. Jager E, Nagata Y, Gnjatic S, Wada H, Stockert E, Karbach J, Dunbar PR, Lee SY, Jungbluth A, Jäger D, Arand M, Ritter G, Cerundolo V, Dupont B, Chen YT, Old JL, Knuth A: Monitoring CD8 T cells responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci, 97: 4760-4765, 2000.
17. Karanikas V, Tsochas S, Boukas K, Kerenidi T, Nakou M, Dahabreh J, Poularakis T, Gourgoulianis KI, Germenis AE: Coexpression patterns of tumor-associated antigen genes by non-small cell lung carcinomas: implications for immunotherapy. Cancer Biol Ther, 7: 345-352, 2008.
18. Jungbluth AA, Busam KJ, Kolb D, Iversen K, Coplan K, Chen YT, Spagnoli GC, Old LJ: Expression of MAGE-antigens in normal tissues and cancer. Int J Cancer, 85: 460-465, 2000.
19. Kim HM, Lim J, Park SK, Kang JS, Lee K, Lee CW, Lee KH, Yun MJ, Yang KH, Han G, Kwon SW, Kim Y, Han SB: Antitumor activity of cytokine-induced killer cells against human lung cancer. Int Immunopharmacol, 7: 1802-1807, 2007.
20. Rosenberg SA: Progress in human tumor immunology and immunotherapy. Nature, 411: 380-384, 2001.
21. Hirschowitz EA, Hiestand DM, Yanelli JR: Vaccines for lung cancers. J Thorac Oncol, 1: 93-104, 2006.
22. Raez LE, Fein S, Podack ER: Lung cancer immunotherapy. Clin Med Res, 3: 221-228, 2005.
23. Juretic A, Spagnoli GC, Shulz-Thater E, Sarcevic B: Cancer/testis tumour-associated antigens: immunohistochemical detection with monoclonal antibodies. Lancet Oncology, 4: 104-109, 2003.
24. Van den Eynde BJ, van den Bruggen P: T cell defined tumor antigens. Curr Opin Immunol, 9: 684-693, 1997.
25. Vansteenkiste J, Zielinski M, Linder A, Dahabre J, Esteban E, Malinowski W, Jassem J, Passlick B, Lehmann F, Brichard VG: Final results of a multi-center, double-blind, randomized, placebo controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol, 25: 398s, 2007.
26. Grah JJ, Samija M, Juretic A, Sarcevic B, Sobat H: Immunohystochemical expression of cancer/testis antigens (MAGE-A3/4, NY-ESO-1) in non-small cell lung cancer: the relationship with clinical-pathological features. Coll Antropol, 32: 731-736, 2008.
27. Sobin LH, Wittekind CH; International Union against Cancer: TNM classification of malignant tumors, 6th edition, Wiley-Liss, New York, 2002.
28. World Health Organization: Histological typing of lung tumours, 3rd edition. World Health Organization, Geneva, 1999.
29. Schulz-Thater E, Juretic A, Dellabona P, Luscher U, Siegrist W, Harder F, Heberer M, Zuber M, Spagnoli GC: MAGE-1 gene product is a cytoplasmic protein. Int J Cancer, 59: 435-439, 1994.
30. Kocher T, Schulz-Thater E, Gaudat F, Schaefer C, Casorati G, Juretic A, Willimann T, Harder F, Heberer M, Spagnoli GC: Identification and intracellular location of MAGE-3 gene product. Cancer Res, 55: 2236-2239, 1995.
31. Rimoldi D, Salvi S, Schultz-Thater E, Spagnoli GC, Cerottini JC: Anti MAGE-3 antibody 57B and anti MAGE-1 antibody C61 can be used to study different proteins of the MAGE-A family. Int J Cancer, 86: 749-751, 2000.
32. Schulz-Thater E, Noppen C, Gaudat F, Durmuller U, Zajac P, Kocher T, Heberer M, Spagnoli GC: NY-ESO-1 tumor associated antigen is a cytoplasmic protein detectable by specific monoclonal antibodies in cell lines and clinical specimens. Br J Cancer, 83: 204-208, 2000.
33. Takahashi K, Shichijo S, Noguchi M, Hirohata M, Itoh K: Identification of MAGE-1 and MAGE-4 proteins in spermatogonia and primary spermatocytes of testis. Cancer Res, 55: 3478-3482, 1995.
34. Weynants P, Lethe B, Brausseur F, Marchand M, Boon T: Expression of MAGE genes by non-small cell lung carcinomas. Int J Cancer, 56: 826-829, 1994.
35. Yoshimatsu P, Lethe B, Brasseur F, Marchand M, Boon T: Expression of melanoma antigen-encoding gene in human lung cancer. J Surg Oncol, 67: 126-129, 1998.
36. Jungbluth AA, Chen YT, Stockert E, Busam KJ, Kolb D, Iversen K, Coplan K, Williamson B, Altorki N, Old LJ: Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer, 92: 856-860, 2001.
37. Tajima K, Obata Y, Tamaki H, Yoshida M, Chen YT, Scanlan MJ, Old LJ, Kuwano H, Takahashi T, Takahashi T, Mitsudomi T: Expression of cancer/testis (CT) antigens in lung cancer. Lung Cancer, 42: 23-33, 2003.
38. Sienel W, Varwerk C, Linder A, Kaiser D, Teschner M, Delire M, Stamatis G, Passlick B: Melanoma associated antigen (MAGE)-A3 expression in stage I and II non-small cell lung cancer: results of a multi-center study. Eur J Cardiothorac Surg, 25: 131-134, 2004.
39. Kavalar R, Sarcevic B, Spagnoli G, Separovic V, Samija M, Terraciano L, Heberer M, Juretic A: Expression of MAGE tumor associated antigens is inversely correlated with tumor differentiation in invasive ductal breast cancers: an immunohistochemical study. Virchows Archiv, 9: 127-131, 2001.
40. Kocher T, Zheng M, Bolli M, Simon R, Forster T, Schultz-Thater E, Remmel E, Noppen C, Schmid U, Ackermann D, Mihatsch MJ, Gasser T, Heberer M, Sauter G, Spagnoli GC: Prognostic relevance of MAGE-A4 tumor antigen expression in transition cell carcinoma of urinary bladder: a tissue microarray study. Int J Cancer, 100: 702-705, 2002.
41. Gotoh K, Yatabe Y, Sugiura T, Takagi K, Ogawa M, Takahashi T, Takahashi T, Mitsudomi T: Frequency of MAGE-3 gene expression in HLA-A2 positive patients with non-small cell lung cancer. Lung Cancer, 20: 117-125, 1998.
42. Jungbluth AA, Antonescu CR, Busam KJ, Iversen K, Kolb D, Coplan K, Chen YT, Stockert E, Ladanyi M, Old LJ: Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7. Int J Cancer, 94: 252-256, 2001.
43. Yoshida A, Abe H, Ohkuri T, Wakita D, Sato M, Noguchi D, Miyamoto M, Morikawa T, Kondo S, Ikeda H, Nishimura T: Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non small cell lung carcinoma and their prognostic significance. Int J Oncol, 28: 1089-1098, 2006.
44. Se JJ, Soria JC, Wang Luo, Khaled AH, Rodolfo CM, Garrett LW, Waun KH, Li M: Activation of melanoma antigen tumor antigens occurs early in lung cacinogenesis. Cancer Res, 61: 7959-7963, 2001.
45. Marchand M, Weynants P, Rankin E, Arienti F, Belli F, Parmiani G, Cascinelli N, Bourlond A, Vanwijck R, Humblet Y, Canon JL, Laurent C, Naeyaert JM, Plagne R, Deraemaeker R, Knuth A, Jager E, Brasseur F, Herman J, Couiae PG, Boon T: Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer, 63: 883-885, 1995.
46. Brichard VG, Lejeune D: GSKs antigen-specific immunotherapy programme: pilot results leading to phase III clinical developement. Vaccine, 25: 61-71, 2007.
47. Vansteenkiste JF, Zielinski M, Dahabreh IJ, Linder A, Lehmann F, Gruselle O, Therasse P, Louahed J, Brichard VG: Association of gene expression signature and clinical efficacy of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in resected stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol, 26: 397s, 2008.
48. Tyagi P, Mirakhur B: MAGRIT: The largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer, 10: 371-374, 2009.
49. Tang H: Cancer vaccines and immunotherapy. Hum Vaccin, 5: 666, 2009.
50. Andersen MH, Junker N, Ellebaek E, Svane IM, Straten P: Therapeutic cancer vaccines in combination with conventional therapy. J Biomed Biotechnol, 2010: 237623, 2010